Sun Pharma acquires Disperzyme and Phlogam brands to strengthen its anti-inflammatory portfolio

Sun Pharma today acquired three brands viz Disperzyme (Trypsin BP 96 mg, Bromelain 180 mg and Rutoside Trihydrate 200 mg), Disperzyme-CD (Trypsin BP 48 mg, Bromelain 90 mg and Rutoside Trihydrate 100 mg) and Phlogam (Trypsin BP 48 mg, Bromelain 90 mg and Rutoside Trihydrate 100 mg) from Aksigen Hospital Care, a Mumbai-based research-driven healthcare entity with over two decades of experience in the healthcare field. All the brands are approved by the Drugs Controller General of India (DCGI) for post-operative inflammation in patients undergoing minor surgery and dental procedures, according to a company statement.

All the brands are approved by the Drugs Controller General of India (DCGI) for post-operative inflammation in patients undergoing minor surgery and dental procedures, said the statement.

Disperzyme and Phlogam are the first enzyme-bioflavonoid combination of Trypsin, Bromelain and Rutoside (TBR) to complete a clinical study in India and get DCGI approval. The brands were registered and launched in India by Aksigen in 2013, added the statement.